Key result
LVA-guided ablation linked to ~21% higher long-term AF/LAT-free survival versus non-guided ablation in non-paroxysmal AF.
Why the study?
The therapeutic effect of low-voltage area (LVA)-guided left atrial linear ablation for non-paroxysmal atrial fibrillation is uncertain.
Does LVA-guided left atrial linear ablation improve long-term AF/LA tachycardia-free survival in patients with drug-refractory non-paroxysmal atrial fibrillation compared to non-LVA-guided ablation?
Cohort (n=145)
No
Does LVA-guided left atrial linear ablation improve long-term AF/LA tachycardia-free survival in patients with drug-refractory non-paroxysmal atrial fibrillation compared to non-LVA-guided ablation?
Absolute Event Rate: 83% vs 62%
p-value: p=0.043
LVA-guided left atrial linear ablation improves long-term arrhythmia-free survival and mitral isthmus block rates compared to non-LVA-guided ablation in patients with drug-refractory non-paroxysmal atrial fibrillation.
LVA-guided ablation was associated with higher arrhythmia-free survival; leaves open benefit in randomized trials of non-paroxysmal AF.
BACKGROUND: The therapeutic effect of low-voltage area (LVA)-guided left atrial (LA) linear ablation for non-paroxysmal atrial fibrillation (non-PAF) is uncertain. We aimed to investigate the efficacy of LA linear ablation based on the preexisting LVA and its effects on LA reverse remodeling in non-PAF patients. METHODS: We retrospectively evaluated 145 consecutive patients who underwent radiofrequency catheter ablation for drug-refractory non-PAF. CARTO-guided bipolar voltage mapping was performed in atrial fibrillation (AF). LVA was defined as sites with voltage ≤ 0.5 mV. If circumferential pulmonary vein isolation couldn't convert AF into sinus rhythm, additional LA linear ablation was performed preferentially at sites within LVA. RESULTS: After a mean follow-up duration of 48 ± 33 months, 29 of 145 patients had drugs-refractory AF/LA tachycardia recurrence. Low LA emptying fraction, large LA size and high extent of LVA were associated with AF recurrence. There were 136 patients undergoing LA linear ablation. The rate of linear block at the mitral isthmus was significantly higher via LVA-guided than non-LVA-guided linear ablation. Patients undergoing LVA-guided linear ablation had larger LA size and higher extent of LVA, but the long-term AF/LA tachycardia-free survival rate was higher than the non-LVA-guided group. The LA reverse remodeling effects by resuming sinus rhythm were noted even in patients with a diseased left atrium undergoing extensive LA linear ablation. CONCLUSIONS: LVA-guided linear ablation through targeting the arrhythmogenic LVA and reducing LA mass provides a better clinical outcome than non-LVA guided linear ablation, and outweighs the harmful effects of iatrogenic scaring in non-PAF patients.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2021) conducted a cohort in Drug-refractory non-paroxysmal atrial fibrillation (n=145). Low-voltage area (LVA)-guided left atrial linear ablation vs. Non-LVA-guided left atrial linear ablation was evaluated on Long-term AF/LAT-free survival rate (p=0.043). LVA-guided left atrial linear ablation resulted in a higher long-term AF/LAT-free survival rate compared to non-LVA-guided linear ablation (83% vs. 62%, p=0.043) in patients with non-paroxysmal atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: